Medical products maker Stryker Corp. increases quarterly dividend

Postado Dezembro 07, 2017

Los Angeles Capital Management & Equity Research Inc.'s holdings in Stryker were worth $4,558,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of SYK. Fifth Third Bancorp raised its holdings in Stryker by 0.7% during the 1st quarter. San Francisco Sentry Investment Group CA now owns 1,005 shares of the medical technology company's stock valued at $143,000 after acquiring an additional 325 shares in the last quarter. San Francisco Sentry Investment Group CA grew its position in shares of Stryker by 47.8% during the third quarter. Banque Pictet & Cie SA acquired a new position in shares of Stryker in the 1st quarter valued at about $994,000. Finally, Thrivent Financial For Lutherans increased its holdings in shares of Stryker by 8.0% in the 1st quarter. Thrivent Financial For Lutherans now owns 14,840 shares of the medical technology company's stock valued at $1,913,000 after purchasing an additional 1,100 shares during the period. Institutional investors and hedge funds own 74.97% of the company's stock.

Stryker Corporation (SYK) traded up $0.98 during trading on Thursday, reaching $155.73. The company's stock had a trading volume of 997,961 shares, compared to its average volume of 1,176,642. Stryker has a 12 month low of $111.22 and a 12 month high of $160.62. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.37 and a quick ratio of 1.61. The firm has a market capitalization of $57,910.00, a price-to-earnings ratio of 24.63, a P/E/G ratio of 2.45 and a beta of 0.79.

Stryker Corporation (NYSE:SYK) last posted its quarterly earnings data on Thursday, October 26th. Commerzbank Aktiengesellschaft FI now owns 49,160 shares of the medical technology company's stock worth $6,982,000 after acquiring an additional 38,293 shares during the last quarter. The company had revenue of $3.01 billion for the quarter, compared to analyst estimates of $2.97 billion. The transaction is expected to be dilutive to Stryker's 2018 adjusted net earnings per diluted share [1] by approximately $0.04 and accretive thereafter. Stryker's revenue for the quarter was up 6.1% compared to the same quarter past year.

A number of equities analysts have recently issued reports on SYK shares.

In related news, insider Lonny J. Carpenter sold 5,000 shares of the stock in a transaction that occurred on Friday, November 3rd. The stock was acquired at an average price of $12.24 per share, with a total value of $122,400.00. Following the completion of the transaction, the insider now directly owns 83,207 shares in the company, valued at $12,925,375.38. Additional information concerning these and other factors is contained in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K.

Stryker Corporation is a medical technology company.

ILLEGAL ACTIVITY NOTICE: "Stryker Corporation (SYK) Given Consensus Rating of "Hold" by Analysts" was reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. Wells Fargo & Company raised their target price on shares of Stryker from $160.00 to $166.00 in a research report on Friday, October 27th. Piper Jaffray Companies reaffirmed an "overweight" rating and set a $148.00 price objective on shares of Stryker in a research note on Thursday, August 24th. SunTrust Banks reissued a "buy" rating and issued a $161.00 price target on shares of Stryker in a research note on Monday, October 2nd. BidaskClub cut Stryker from a buy rating to a hold rating in a report on Saturday, August 26th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and thirteen have issued a buy rating to the company's stock. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $151.40.